-
Drug K approved for first-line treatment of esophageal cancer
Time of Update: 2021-04-20
. According to the Global Cancer (GLOBOCAN) statistical report released by the International Agency for Research on Cancer of the World Health Organization, the number of new cases of esophageal cancer worldwide
-
K drug treatment of high-risk early triple-negative breast cancer encounters a complete response letter from the US FDA
Time of Update: 2021-04-19
The sBLA seeks to approve Keytruda for the treatment of high-risk early triple-negative breast cancer (TNBC) patients, specifically: Keytruda combined with chemotherapy for neoadjuvant (preoperative) treatment, and then Keytruda as a single drug for adjuvant (postoperative) treatment.
-
"K drug" single-agent adjuvant treatment of renal cell carcinoma phase III study yields positive
Time of Update: 2021-04-18
CCR: Androgen deprivation therapy combined with piperacillil does not improve RB-positive metastasis Sex hormone-sensitive prostate cancer prognosis JTO: Anti-PD-1 monoclonal antibody combination regimen has better survival results in the first-line treatment of advanced non-small cell lung cancer.
-
Lancet oncol: Pembrolizumab can significantly improve the quality of life of patients with metastatic colorectal cancer with MSI-H or dMMR
Time of Update: 2021-04-13
instability or defective mismatch repair, can significantly prolong the progression-free survival of patients . >Compared with chemotherapy, pembrolizumab
-
Clin Gastroenterology H: The postoperative recurrence rate of Crohn's disease and the effect of immunosuppression and biological therapy on its recurrence
Time of Update: 2021-04-13
The Rutgeerts scoring system is an effective tool for assessing the recurrence of Crohn's disease (CD) patients after ileocecal resection.
-
Clin Gastroenterology H: Oral hormones can relieve the symptoms of dysphagia in patients with eosinophilic esophagitis
Time of Update: 2021-04-13
This study aims to explore the alleviating effect of budesonide oral suspension (BOS) on dysphagia in patients with EoE.
-
Clin Gastroenterology H: The level of tumor necrosis factor produced by blood monocytes can be used
Time of Update: 2021-04-13
This study found that the PBMC (especially CD14 + cells) of patients with IBD produce high levels of TNF, which can identify patients who are most likely to have a clinical response to infliximab treatment.
-
Clin Gastroenterology H: The relationship between non-alcoholic fatty liver and cancer in a large Chinese cohort
Time of Update: 2021-04-13
In men with NAFLD, higher ALT levels are associated with higher risks of thyroid cancer and hepatocellular carcinoma.
-
Clin Gastroenterology H: Diet therapy can induce rapid remission in children with active Crohn's disease
Time of Update: 2021-04-13
This study confirmed that for pediatric patients with CD in the active stage of disease, diet therapy (CDED and EEN) can quickly induce disease remission.
-
Biotech: Resubmit the H-share listing application to the Hong Kong Stock Exchange
Time of Update: 2021-03-26
On March 23, Biotech announced that the company is in the process of applying for the public issuance of overseas listed foreign shares (H shares) and listing on the main board of the Hong Kong Stock Exchange.
-
, 2B3D is more than single nucleotide detected in nearly 30% of MSI-H patients
Time of Update: 2021-03-23
【Introduction】Professor Li Zhi, Director of the Department of Pathology, Guangdong Provincial People's Hospital, led a meta-analysis of the positive detection rate data of Panels at different MSI detection sites in the Chinese population.
-
PD-1 new drug PKO/K drug biosimilar drug who will win?
Time of Update: 2021-03-22
announced the termination of the clinical development of its PD-1 product. This is the first company in China to suspend the development of PD-1. A week ago, Luye Pharma just announced
-
Surgery PD-1: After O drug, K drug, I drug, the first indication of T drug was also withdrawn
Time of Update: 2021-03-22
industry colleagues to open in April ▲Recently (March 8, 2021), Roche announced the withdrawal of its PD-L1 antibody Tecentriq from the United States for the second-line treatment of this indication for metastatic urothelial cancer Roche said
-
Stroke Using Non-Vitamin K Antagonist Oral Anticoagulants
Time of Update: 2021-03-21
: inherit;"> published a research article on the disease areas prestigious journal Stroke, prospective, multicenter, multinational, cases not matched control study was designed to (1) explore can predict the occurrence
-
Clin Gastroenterology H: The degree of remission of patients with type 2 diabetes is negatively
Time of Update: 2021-03-18
Inverse Association Between Fatty Liver at Baseline Ultrasonography and Remission of Type 2 Diabetes Over a 2-Year Follow-up Period .
-
Heart: The latest results of real-world analysis once again confirmed the clinical benefits and safety of non-vitamin K antagonist oral anticoagulants
Time of Update: 2021-03-18
The researchers compared the risk of all-cause mortality, non-hemorrhagic stroke/systemic embolism, and major bleeding in all patients within 2 years.
-
Clin Gastroenterology H: Adolescent women with irritable bowel syndrome have a higher risk of endometriosis
Time of Update: 2021-03-18
Irritable bowel syndrome (IBS) is a functional gastrointestinal disease characterized by frequent occurrence of abdominal pain and diarrhea.
-
Clin Gastroenterology H: Efficacy and safety analysis of 5-HT-4 receptor agonist Misapride in the treatment of patients with irritable bowel syndrome
Time of Update: 2021-03-18
Therefore, this study aims to explore the efficacy and safety of Misapride in the treatment of patients with irritable bowel syndrome .
-
Clin Gastroenterology H: A randomized double-blind trial confirms that antibiotics will not reduce
Time of Update: 2021-03-18
The results of the study showed that there was no significant difference in the median length of stay between patients receiving antibiotic treatment and the placebo group ((40.
-
Clin Gastroenterology H: The baseline clearance of infliximab is related to the need for colectomy in patients with acute severe ulcerative colitis
Time of Update: 2021-03-17
The results of the study showed that among 39 ASUC patients, the median baseline infliximab clearance rate of 6-month patients who required colectomy was higher than that of patients who did not undergo colectomy (0.
